Tysabri Touch Form Pdf. Web per the requirements of the touch prescribing program, authorized infusion sites must: Verify that the patient is currently authorized to receive tysabri prior to each infusion provide the patient with a copy of the patient medication guide prior to each infusion
Receiving Your TYSABRI® (natalizumab) Infusion
Web per the requirements of the touch prescribing program, authorized infusion sites must: Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Unified commitment to health phone: This document may not be part of the latest approved prescribing program tysabri outreach: Information prescribers, infusion center healthcare providers, and patients with the risk of progressive multifocal leukoencephalopathy (pml) associated with tysabri including the increased risk of pml with treatment duration and prior immunosuppressant use. Web tysabri increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (pml)—that most leads to death instead severe disability. Web tysabri treatment continuation form tysabri (natalizumab) 300 mg concentrate solution for infusion this form should be read carefully before continuing tysabri treatment for more than 2 years. Web current as of 6/1/2013. If diagnosis of relapsing forms of multiple sclerosis (ms). Reduce administrative burden/paperwork for prescribers and infusion sites.
Tysabri increases the risk of pml. Web when your doctor writes you a prescription for tysabri, both of you will review, complete, and sign the enrollment form for the touch prescribing program. Web current as of 6/1/2013. Maintain compliance with the touch prescribing program. Web the touch prescribing program has designed to: This document may not be part of the latest approved prescribing program tysabri outreach: Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Web tysabri treatment continuation form tysabri (natalizumab) 300 mg concentrate solution for infusion this form should be read carefully before continuing tysabri treatment for more than 2 years. Streamline communication to/from prescribers and infusion sites. Verify that the patient is currently authorized to receive tysabri prior to each infusion provide the patient with a copy of the patient medication guide prior to each infusion Web per the requirements of the touch prescribing program, authorized infusion sites must:
